Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)‘s stock had its “buy” rating reissued by analysts at Wells Fargo & Company in a research report issued to clients and investors on Tuesday.

A number of other equities research analysts have also issued reports on the stock. Zacks Investment Research lowered shares of Jazz Pharmaceuticals PLC from a “hold” rating to a “sell” rating in a research note on Tuesday, May 2nd. Mizuho cut their target price on shares of Jazz Pharmaceuticals PLC from $150.00 to $144.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 31st. Cowen and Company restated an “outperform” rating and issued a $190.00 target price on shares of Jazz Pharmaceuticals PLC in a research note on Wednesday, May 10th. Deutsche Bank AG set a $178.00 target price on shares of Jazz Pharmaceuticals PLC and gave the company a “buy” rating in a research note on Monday, July 17th. Finally, Cantor Fitzgerald reiterated a “buy” rating and set a $197.00 price objective on shares of Jazz Pharmaceuticals PLC in a research note on Tuesday, June 27th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and nineteen have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $180.96.

Shares of Jazz Pharmaceuticals PLC (NASDAQ JAZZ) traded up 0.03% on Tuesday, reaching $146.14. The company had a trading volume of 376,853 shares. The company has a 50 day moving average of $152.07 and a 200-day moving average of $148.41. Jazz Pharmaceuticals PLC has a 52 week low of $95.80 and a 52 week high of $163.75. The company has a market capitalization of $8.78 billion, a P/E ratio of 22.51 and a beta of 1.10.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last issued its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.85 by $0.13. The company had revenue of $394.39 million during the quarter, compared to analyst estimates of $410.83 million. Jazz Pharmaceuticals PLC had a net margin of 25.69% and a return on equity of 22.75%. The business’s revenue for the quarter was up 3.5% compared to the same quarter last year. During the same quarter last year, the company posted $2.67 EPS. Analysts predict that Jazz Pharmaceuticals PLC will post $10.88 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This article was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://www.watchlistnews.com/jazz-pharmaceuticals-plc-jazz-stock-rating-reaffirmed-by-wells-fargo-company/1530202.html.

In other Jazz Pharmaceuticals PLC news, Director Rick E. Winningham sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 1st. The shares were sold at an average price of $150.00, for a total value of $750,000.00. Following the sale, the director now owns 10,391 shares in the company, valued at $1,558,650. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Michael Patrick Miller sold 200 shares of the firm’s stock in a transaction that occurred on Thursday, June 15th. The shares were sold at an average price of $150.65, for a total transaction of $30,130.00. Following the completion of the sale, the executive vice president now owns 22,223 shares in the company, valued at approximately $3,347,894.95. The disclosure for this sale can be found here. Insiders sold 12,917 shares of company stock worth $1,973,227 in the last 90 days. 4.30% of the stock is owned by company insiders.

Several large investors have recently made changes to their positions in JAZZ. Suntrust Banks Inc. purchased a new stake in shares of Jazz Pharmaceuticals PLC during the first quarter valued at approximately $1,501,000. Bank of New York Mellon Corp raised its stake in shares of Jazz Pharmaceuticals PLC by 3.2% in the first quarter. Bank of New York Mellon Corp now owns 1,447,760 shares of the specialty pharmaceutical company’s stock valued at $210,114,000 after buying an additional 44,973 shares during the last quarter. Daiwa Securities Group Inc. raised its stake in shares of Jazz Pharmaceuticals PLC by 12.9% in the first quarter. Daiwa Securities Group Inc. now owns 1,750 shares of the specialty pharmaceutical company’s stock valued at $254,000 after buying an additional 200 shares during the last quarter. DekaBank Deutsche Girozentrale raised its stake in shares of Jazz Pharmaceuticals PLC by 8.2% in the first quarter. DekaBank Deutsche Girozentrale now owns 59,683 shares of the specialty pharmaceutical company’s stock valued at $8,725,000 after buying an additional 4,527 shares during the last quarter. Finally, American Century Companies Inc. raised its stake in shares of Jazz Pharmaceuticals PLC by 1,453.2% in the first quarter. American Century Companies Inc. now owns 235,806 shares of the specialty pharmaceutical company’s stock valued at $34,223,000 after buying an additional 220,624 shares during the last quarter. Institutional investors own 88.24% of the company’s stock.

Jazz Pharmaceuticals PLC Company Profile

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Analyst Recommendations for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.